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16-year experience with the use of autogenous composite
vein bypass grafts for infrainguinal arterial reconstruction.
METHODS
A retrospective evaluation was performed on all infrain-
guinal bypasses using composite vein grafts done at the
Brigham and Women’s Hospital between June 1983 and
September 1999. Only grafts that consisted of all autogenous
venous segments were considered. Data were retrieved from
a computerized registry in which demographics, risk factors,
procedure variables, and follow-up information have been
prospectively entered for all vascular surgery patients at our
institution since 1975. In addition, detailed review of com-
puterized in-patient records, office charts, operative reports,
vascular laboratory reports and angiographic findings was
performed. Over the last 12 years, increasing reliance has
been placed on duplex scanning for preoperative mapping of
ectopic veins and for postoperative graft surveillance.
The techniques of vein harvest and preparation and per-
formance of the venovenostomy have been previously
described.3 In general, a two-team approach was adopted for
exposure of the inflow and outflow sites and for harvesting
the ectopic vein segments. Our strategy for the prioritization
of vein usage was predicated on the principle of using the
best vein available for the clinical problem at hand. In these
complex cases, duplex vein-mapping guided the order in
which these alternative veins were used. Apart from obvious
thrombosis, wall-thickening and noncompressibility, the
most useful information was whether the vein was present. If
Infrainguinal arterial reconstruction for limb salvage in
the absence of adequate greater saphenous vein (GSV)
remains a challenging problem in contemporary vascular
practice. The high incidence of coronary artery bypass
grafting and reoperative lower extremity bypass surgery
has resulted in the lack of usable GSV becoming an
increasingly common clinical scenario. Since the early
1980s, our strong preference has been to complete all
infrainguinal reconstructions with autogenous vein, and
we have been encouraged by the excellent long-term
patency of these grafts.1,2 Unfortunately, many patients
lack a single segment of vein of sufficient length to com-
plete the reconstruction. In an analysis of lower extremity
revascularizations in our institution over the past 20 years,
the need for ectopic/composite vein usage has increased
from 5% (before 1987) to the present 19% of our lower
extremity bypass procedures. In this article, we report our
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Purpose: Lower extremity arterial reconstruction in the absence of adequate greater saphenous vein remains a challeng-
ing problem in contemporary vascular practice. The purpose of this review is to evaluate the long-term results of auto-
genous composite vein grafts used for infrainguinal arterial bypass grafting.
Methods: We retrospectively evaluated a prospective vascular registry and reviewed inpatient and office records.
Results: From June 1983 to September 1999, 165 autogenous composite vein infrainguinal bypass grafts were per-
formed in 154 patients (87 men, 67 women; mean age, 69 years). The mean follow-up was 25 months (range, 3-147).
Patients had the usual risk factors, including a 30% incidence of prior coronary bypass grafting. Forty-eight percent
of bypass grafts were performed after failed previous reconstructions, and 90% were performed for limb salvage. The
conduits were comprised of 2 segments (75%), 3 segments (23%), and 4 segments (2%). The distal anastomosis was
at the popliteal level in 17% and the tibial/pedal level in 83%. The 30-day operative mortality rate was 1.8%.
Perioperative graft failure (< 30 days) occurred in 18 bypass grafts (11%), resulting in early amputation (< 30 days)
in 1.2%. The overall 5-year cumulative patency rates were 44% ± 5% for primary patency, 63% ± 5% for primary-
assisted patency (PAP), and 65% ± 5% for secondary patency (SP). A high revision rate for stenosis or thrombosis was
required during follow-up to maintain patency of the grafts (27%). Limb salvage was 81% ± 5% at 5 years. Primary
reconstructions with composite vein fared significantly better than secondary reconstructions (SP 76% vs 54% at 5
years, P < .01). Arm vein composites showed superior patency compared with greater saphenous vein composites (SP
79% vs 61% at 5 years, P < .05).
Conclusions: Infrainguinal reconstruction with autogenous composite vein results in durable graft patency and limb sal-
vage rates in patients with few alternatives for revascularization. Intensive graft surveillance with aggressive graft revi-
sion is necessary to achieve these results. (J Vasc Surg 2001;33:259-65.)
a minimum diameter of 2 to 3 mm was seen in an otherwise
normal vein on duplex scan, it was explored. Our intraoper-
ative criteria for an optimal vein were a minimum diameter
of 3.5 to 4 mm, easy distensibility with gentle inflation and
absence of sclerotic areas. Vein segments that did not meet
these criteria were excised or repaired (“upgraded”). Intra-
operative angioscopy was not used in these cases.
The various vein segments were left in situ until arterial
exposure was complete to minimize ischemic injury to the
conduit. This also facilitated accurate determination of the
length of conduit necessary to complete the bypass. The vein
segments were oriented such that the largest caliber was
placed proximally, creating a gradual taper of the composite
graft to optimize the size match between the graft and the
native vessel at the anastomoses. Valve-lysis, when required,
was performed ex vivo with the retrograde modified Mills
valvulotome with the vein under constant irrigation with a
heparin/papaverine solution. This was completed before the
venovenostomy was performed. The anastomosis was con-
structed by spatulating the ends of each vein, securing the
heel and toe with 7-0 polypropylene suture, and running
toward the middle, taking care not to purse-string the anas-
tomosis. Completion arteriography was routinely performed
in all cases to visualize the venovenostomy and the distal
anastomosis. Recently, we have also used intraoperative
duplex imaging to identify occult problems in the conduit.
The vein segments that have been utilized included
GSV remnants, lesser saphenous vein (LSV), basilic vein
(BV), and cephalic vein (CV) from all available extremi-
ties. The BV was almost always used in a nonreversed ori-
entation because of its usual tapered anatomy. Because
the length of conduit was the limiting factor in these
cases, we strived to use the most acceptable distal inflow
and proximal outflow sites possible. Apart from aspirin,
postoperative anticoagulation was used selectively in a
minority of cases.
Follow-up examinations occurred within the first
month of surgery, then at 3 monthly intervals for the first
year, and semiannually thereafter. Since 1988, duplex
scanning has been added to noninvasive hemodynamic
studies (ankle-brachial index) for detection of occult graft
lesions. A return of symptoms, change in physical exami-
nation, focal increase in graft velocity (ratio > 3:1), and
decreased overall graft velocity (< 45 cm/s) in a normal
caliber graft were considered evidence of significant
lesions and usually lead to arteriography.4
Minor amputations were defined as those resulting in a
foot that could still be used for ambulation. Limb salvage
was correspondingly defined as freedom from major ampu-
tation. Primary patency (PP), primary-assisted patency
(PAP), and secondary patency (SP) rates were defined in
accordance with the suggested reporting standards of the
Ad Hoc Committee of the Society for Vascular Surgery and
the North American Chapter of the International Society
for Cardiovascular Surgery.5 Survival, graft patency, and
limb salvage rates were calculated with the life-table
method. SEs were calculated with the Greenwood method,
and comparisons were made between groups with the
Mantel-Cox log-rank analysis. Categoric variables were
compared with χ2 analysis. A P value of less than .05 was
considered to represent statistical significance. Loss to 
follow-up was defined as the last patient visit or contact
being more than 18 months.
RESULTS
Over the 16-year period, 165 autogenous composite
vein infrainguinal bypass grafts were performed in 154
patients. There were 87 men and 67 women, with a mean
age of 69 years (range, 35-88). Risk factors included dia-
betes mellitus (54%), hypertension (62%), cigarette smok-
ing (42%), and coronary artery disease (69%) with 30% of
patients having undergone prior coronary artery bypass
grafting. Four percent of patients had dialysis-dependent
renal failure. Ninety percent of the operations were per-
formed for limb salvage (rest pain, 36%; ulcer, 33%; gan-
grene, 21%); the rest were for severe claudication.
Forty-eight percent of bypass grafts were performed after
failed previous reconstructions.
Reasons for using composite vein included lack of a
sufficient single segment vein conduit in 69%, excision of
a poor quality vein segment (vein upgrade) in 21%, and
unknown in 10%. The conduits were comprised of 2 seg-
ments (75%), 3 segments (23%), or 4 segments (2%).
Sixty-five (39%) were solely GSV composites, 36 (22%)
were arm vein (AV) composites, and 64 (39%) were vari-
ous arm-leg vein combinations. The proximal anastomosis
arose from the common femoral artery in 68%, the proxi-
mal superficial femoral artery in 12%, the distal superficial
femoral artery in 8%, the profunda femoris artery in 6%,
and the popliteal artery in 6%. The distal anastomosis was
located at the above-knee popliteal artery in 2%, below-
knee popliteal artery in 15%, tibioperoneal trunk in 3%,
anterior tibial artery in 25%, posterior tibial artery in 19%,
peroneal artery in 26%, and dorsalis pedis artery in 10%.
The overall postoperative morbidity rate was 29%,
including cardiac (9%) (myocardial infarction, congestive
cardiac failure, arrhythmia), wound infection (3.6%), and
hematoma/seroma (5.4%). Major morbidity (myocardial
infarction, stroke, renal and pulmonary failure) occurred
in 7%. Perioperative graft failure (< 30 days) occurred in
18 bypass grafts (11%), resulting in early amputation (< 30
days) in 1.2%. Thirty-day operative mortality occurred in
three patients (1.8%) from myocardial infarction and
stroke. The mean follow-up was 25 months (range, 3-
147). Thirteen percent of patients were lost to follow-up.
The overall 5-year cumulative PP rate was 44% ± 5%,
the PAP rate was 63% ± 5%, and the SP rate was 65% ± 5%.
Overall limb salvage in patients with limb-threatening
ischemia was 81% ± 5% at 5 years (Fig 1 and Appendix A).
The 5-year survival rate was 71% ± 5%. Subgroup analysis
revealed that the 5-year PAP was significantly better for pri-
mary reconstructions than for secondary bypasses (75% ±
6% vs 36% ± 5%, P < .001). Similarly, primary bypasses had
a significantly better SP than repeat bypasses (76% ± 6% vs
54% ± 7%, P < .01) (Fig 2 and Appendix B).
Furthermore, AV composites showed superior PP and
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SP compared with GSV composites (61% ± 9% vs 37% ± 7%,
P < .02, and 79% ± 8% vs 61% ± 8%, P < .05, respectively)
(Fig 3 and Appendix C). There was no significant difference
when GSV composites were compared with various arm-leg
vein combinations. We also found no difference in patency
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whether two segments (one venovenostomy) or more than
two segments were created (SP 65% ± 6% vs 70% ± 9%,
respectively, P = .3) (Fig 4 and Appendix D).
During follow-up, significant stenotic lesions were
identified with duplex scanning or arteriography in 32
Fig 1. Overall patency and limb salvage of composite vein bypass grafts.
Fig 2. Secondary patency of primary versus secondary bypass grafts.
grafts (20%). The sites of the lesions were distributed as
follows: distal anastomosis (32%), venovenostomy (30%),
proximal anastomosis (22%), and midgraft residual valve
cusp (16%). This information was not available in four
grafts. Among the stenotic grafts, 47% had 1 lesion, 31%
had 2 lesions, and 9% had more than 2 lesions. In 13% of
grafts, the number of lesions could not be determined.
The overall graft revision rate (for stenosis or thrombosis)
for the entire series was 27%. The revision rate for GSV
composites was 29%, for AV composites, 17%, and for
arm-leg vein composites, 30%.
DISCUSSION
Single-segment GSV remains the conduit of choice
for infrainguinal arterial reconstruction with 5-year
cumulative PP rates of 70%, SP rates of 80%, and limb sal-
vage rates of 90%.6 When GSV is either unusable or
unavailable, limb salvage becomes a more difficult chal-
lenge. There is little doubt that autogenous conduits are
superior to prosthetic grafts in the infrapopliteal loca-
tion.7 However, the extent to which ectopic vein seg-
ments are used to form a long composite vein graft is
highly variable primarily because the procedure requires
familiarity with sources of ectopic vein and the prolonged
operation often required. Of greater influence in the
choice of alternative conduits is a common perception
among many vascular surgeons that one or more ven-
ovenostomies tend to diminish durability. This notion has
not been supported by the literature, but there are few
large series of autogenous composite vein grafts reported
that define long-term performance.
Our institutional preference has been to exhaust all
usable autogenous vein sources for limb salvage. In this series
of 165 composite grafts, the overall 5-year PAP and SP rates
were 63% and 65%, respectively. Limb salvage in this chal-
lenging patient population was 79% at 5 years. This was
achieved despite a higher number of adverse factors, includ-
ing a 48% incidence of failed previous bypass grafts and an
83% incidence of distal anastomosis at the tibial/pedal level.
In the patients who underwent primary bypasses, the 5-year
PAP rate of 75% approached that of single-segment GSV
conduits. Although the total morbidity rate of this approach
may seem high at 29%, most of it was due to early graft fail-
ure (11%), which is expected for these challenging situations.
Wound complications (infection, hematoma, seroma) com-
prised another 9%. Major morbidity (myocardial infarction,
stroke, renal and respiratory failure) occurred in only 7%,
thus justifying our aggressive approach.
A somewhat remarkable finding is the superior patency
of AV composites compared with GSV composites. There
was no significant difference in the risk factor profiles of
each group that may have contributed to this observation.
The 5-year patency rate of our AV composites (PP, 61%;
SP, 79%) is similar or better than those reported in the lit-
erature.8-13 Unlike AV composite grafts, which are always
performed because of the shorter length of the veins, most
GSV composites were upgrades in which a suboptimal seg-
ment of the vein was excised (45 upgraded grafts vs 20
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Fig 3. Patency rates of AV versus GSV composites. AV, Arm vein; GSV, greater saphenous vein.
remnant GSV grafts). This may explain the poorer perfor-
mance of the GSV composites because the upgraded graft
may remain inherently a poor-quality conduit.
The common perception that venovenostomy
adversely affects the performance of composite grafts
should be addressed. We found no difference in 5-year
patency rates whether one or more venovenostomies were
performed. Two other studies have shown that patency
rates are not influenced by the number of segments.12,14
Composite grafts, however, are more susceptible to
stenotic lesions than single-segment conduits. After an
intensive graft surveillance protocol, we detected signifi-
cant stenotic lesions in 20% of grafts. The overall graft
revision rate was high (27%) compared with our experi-
ence with single-segment grafts (6%-7%).15 As such, PP
rates will be lower, but the more relevant and important
PAP and SP rates are encouraging. The distal anastomosis
and the venovenostomy were the most commonly affected
areas, and multiple lesions were present in at least 40% of
grafts. Duplex scanning can detect these lesions that may
be asymptomatic and often easily rectified. Preservation of
graft function in this group of patients is crucial because
the composite graft is usually the last durable option for
limb salvage.
In conclusion, infrainguinal arterial reconstruction
with autogenous composite vein results in durable graft
patency and limb salvage rates in patients with no other
realistic alternatives for revascularization. The high inci-
dence of vein graft stenosis mandates an aggressive sur-
veillance protocol and graft revision to achieve these
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excellent results. The need for multiple vein segments
should not discourage its use in limb salvage situations.
We are grateful to Ms Julie Lombara for her assistance
in data management.
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DISCUSSION
Dr George Andros (Encino, Calif). First of all, David, thank
you for sending me that manuscript in a timely fashion.
The problem with the all-autogenous approach is simply a
matter of supply and demand; many more patients need bypass
operations than there are available saphenous veins. With the
inclusion of arm veins, the supply is still insufficient, especially
because of the growing number of very long grafts extending to
distal targets. Thus, in an all-autogenous cosmos, the all-autoge-
nous composite graft is both natural and inevitable. Today, we
have before us the long-term results of this composite bypass
strategy from a leading group, some might say the leading group,
to pioneer the all-autogenous revascularization of the leg.
The authors present the outcomes of 165 grafts in 154
patients with a 16-year follow-up. These numbers suggest that
the average clinical vascular fellow will have experience with about
10 to 12 composite procedures, certainly an adequate number for
indoctrination into the technique. What percent of your total
infrainguinal bypasses employ the autogenous composite strat-
egy? With this practical bit of information, we can all approximate
how frequently we may be called on to use vein splicing tech-
niques ourselves.
Using a systematic graft surveillance program, the authors
obtained an assisted primary patency rate of 63% and a limb sal-
vage rate of 81% at 5 years. They also observed that secondary
stenotic lesions were not unusually common at the site of ven-
ovenostomy. This, as David pointed out, is contrary to what most
surgeons had feared, notwithstanding composite grafts that
require revision three to four times more often than single length
conduits. How do you explain this increased revision rate if the
appearance of secondary stenotic lesions at the venovenostomies
is relatively minor? The roughly equivalent patencies you
obtained with conduits having one, two, and three venovenos-
tomies attest to your technical skill and your ability to clinically
select usable segments. Overall it’s a worthy achievement.
But, there are some problems.
First, there’s the surprising longevity of your patient popula-
tion operated on for those most compelling indications, rest pain
and ischemic necrosis. How do you account for a 5-year mortal-
ity of only 29%? Most surgical series of claudicants and limb sal-
vage patients report a 5-year mortality of at least 50%, irrespective
of whether the operation was a first-time or redo procedure.
Moreover, mortality rates three times greater than those pre-
sented here have been observed in patients who had nothing
more than an SFA PTA, or perhaps no intervention at all.
In fairness, other surgeons have reported unusually good
mortality rates after multiple reoperations, most often with arm
veins. Do your operations confer extended survival to your
patient cohort, or does the multiple revascularization procedure
somehow select a more long-lived subset? How does the group’s
mortality compare with the overall group of infrainguinal proce-
dures that you do? This critical statistic leads one to wonder if
these patients and their limbs were somehow less in jeopardy and
might not have needed one of these elegant but complex and
demanding operations.
Equally bewildering is a limb salvage rate that exceeds the
secondary patency rate by 15%. In our experience with limb sal-
vage patients, the ultimate loss of a patent graft is tantamount to
amputation. Could you comment? The near equivalence of your
primary-assisted patency and secondary patency bears witness to
the success of your graft surveillance protocol. Do you recom-
mend subcutaneous tunnels to facilitate duplex scanning?
Finally, I’m inclined to agree with your observation that
primary-assisted patency of first time or primary reconstructions
is better than for secondary operations. I confess I have no bet-
ter reason for concurring with you than we reported the same
thing. This is far from a trivial point. In fact, it may be your
most important observation. Your results with primary opera-
tions at 5 years were commendable at 75%, but the secondary
operations were very disappointing at 36%. If you could have
known that your patency would be that low at 5 years with redo
operations requiring composite grafts, wouldn’t it have been
better to spare the patient the long operation with multiple inci-
sions, the patient many hours of potentially disappointing labor,
by simply inserting a PTFE graft with a vein cuff?
This paper is a bounty of useful information. I recommend it
to you, and I thank the Society for the opportunity of comment-
ing. Thank you.
Dr David K. W. Chew. Thank you, Dr Andros. I hope I can
remember all your questions.
First, I would say that composite vein grafts are done about
19% to 20% of the time at our institution. Probably because of the
referral patterns, we get a lot of patients who have had previous
bypasses elsewhere, and we are aggressive at limb salvage. It
always seems that every time we present a series, we get asked the
same question of why our patients live so long. And I have to sus-
pect that it’s probably better screening. We have a good cardiol-
ogy team, a vascular medicine cardiology team, that works closely
with us to see who would and who would not tolerate a revascu-
larization procedure in the extremity. Although, for our sec-
ondary bypass group the patency rates were not as good as the
primary bypasses, I think it’s hard to predict who would do well
and who would not. And our current preference is still that if
there is a distal target vessel and the patient has usable vein, we
have been able to two-team these operations and get them done
within 3 hours. So I don’t think it really is as long as what most
people would think it is if you adopt a two-team approach.
The venovenostomy was originally thought to be the most
problematic site, but, as shown in this study, I think that the ve-
novenostomy is just another potential site of a problem. It is an
anastomosis that is just as problematic as the proximal or the dis-
tal anastomosis. Finally, I think that primary patency in these
grafts mean nothing. With aggressive graft surveillance, we can
salvage these grafts and fix them before they go down. We feel
that this is the most durable option for limb salvage in this chal-
lenging patient population.
Dr Frank T. Padberg, Jr (Newark, NJ). The worst thing in
vascular reconstruction of the lower extremity is bad vein. I’d like
to ask how you defined acceptable or “good” vein? You said you
used vein mapping, and you probably expressed it in your manu-
script, but not in the presentation. What were your criteria for
acceptable vein?
Likewise, we have extended ourselves beyond the use of
greater saphenous, lesser saphenous, and arm vein, into occasion-
ally using branches of the saphenous. My second specific question
was whether or not you have used saphenous branch veins and
whether or not they had any impact on your results?
And thirdly, although I’m sure you defined it in the manu-
script but not in the presentation, I question the term composite
vein. Oftentimes in our usage we use that to refer to a prosthetic
plus a piece of vein, rather than two pieces of vein, which would
be all autogenous. So perhaps autogenous composite would be
more acceptable. Could you please comment?
Dr Chew. Well, I think our experience is that duplex scanning
shows us whether the vein is present or not. Oftentimes, you really
can’t be sure until you take the vein out and see it in the distended
state. We like to see a vein that’s without any sclerotic areas, that
distends evenly, and with a minimum diameter of 3.5 to 4 mm.
Our vein mapping is done with the extremities in the dependent
position, but I think the most useful information is whether the
vein is there or isn’t there. If it warrants exploration, we would
explore the vein and take it out and see whether it will distend.
With regard to your second question, was it the use of lesser
saphenous vein?
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Dr Padberg. Branches of saphenous vein rather that greater
saphenous or lesser saphenous channels specifically.
Dr Chew. If there is a good branch of the greater saphenous
vein, we’ll use it, because I think it works equally well in the
patients with duplicated systems. And if you’re lucky, you get two
nice big duplicated channels, which increases your options.
Dr Padberg. Did those work as well as the others, or did you
have a chance to look at that?
Dr Chew. In the 165 grafts, I remember seeing a small num-
ber where we encountered branches and we used them. Now, I
don’t have the data on the follow-up of these branches.
With regard to composite vein, I know that in the literature it’s
quite confusing, but we refer to all-autogenous composite vein grafts. 
Dr Gregory L. Moneta (Portland, Ore). I was just wonder-
ing, last year we suggested that if you’re going to revise vein grafts
that we ought to do an angiogram before each one because some-
times we find lesions that were not found on the original duplex
study. And you said you found multiple lesions in about 20% of
your grafts that you revised. How many of those did you find with
your initial duplex surveillance, where you found all the lesions,
versus how often did the angiogram really find a lesion that was
missed on the duplex?
Dr Chew. Well, I think most of our vein graft revisions had an
angiogram before revision, but I don’t have the data on what per-
centage was missed on duplex scanning.
Access to Journal of Vascular Surgery Online is reserved for print subscribers!
Full-text access to Journal of Vascular Surgery Online is available for all print subscribers.
To activate your individual online subscription, please visit Journal of Vascular Surgery
Online, point your browser to http://www.mosby.com/jvs, follow the prompts to activate
your online access, and follow the instructions. To activate your account, you will need your
subscriber account number, which you can find on your mailing label (note: the number of
digits in your subscriber account number varies from 6 to 10). See the example below in
which the subscriber account number has been circled:
Sample mailing label
This is your subscription
account number
Personal subscriptions to Journal of Vascular Surgery Online are for individual use only
and may not be transferred. Use of Journal of Vascular Surgery Online is subject to agree-
ment to the terms and conditions as indicated online.
**************************3-DIGIT 001
SJ P1
FEB00 J024 C: 1  1234567-89  U 05/00 Q: 1
J. H. DOE, MD
531 MAIN ST
CENTER CITY, NY 10001-001
